EU Approves DAWNZERA, a New RNA Therapy for Hereditary Angioedema

CARLSBAD, CA & TOKYO, JAPAN – January 21, 2026 – The European Commission has granted marketing authorization for DAWNZERA™ (donidalorsen), an innovative RNA-targeted therapy developed by Ionis Pharmaceuticals, offering a new preventative treatment for thousands of Europeans living with the rare and debilitating genetic condition, hereditary angioedema (HAE). The approval clears the path for commercialization by partner Otsuka Pharmaceutical, heralding a new era of less frequent, self-administered treatment for adults and adolescents aged 12 and older.

The decision marks a significant milestone for patients burdened by the constant threat of severe, unpredictable, and potentially life-threatening swelling attacks. DAWNZERA is the first and only RNA-based medicine for HAE, designed to be self-injected subcutaneously just once every four or eight weeks, a schedule that promises to dramatically reduce the treatment burden and improve quality of life.

A New Dawn for Patient Autonomy

Hereditary angioedema affects an estimated 1 in 50,000 people globally, with around 15,000 individuals in Europe navigating its challenges. The condition is caused by a genetic defect that leads to recurrent episodes of severe swelling (angioedema) in various parts of the body, including the hands, feet, face, and, most dangerously, the throat, where it can cause asphyxiation. The unpredictable nature of these attacks forces many patients to live in a state of constant anxiety, often limiting their social, professional, and personal lives.

DAWNZERA directly confronts the disease's mechanism by using RNA-targeted technology to reduce the production of plasma prekallikrein (PKK), a key protein that triggers the inflammatory cascade leading to HAE attacks. The European approval was based on robust data from the Phase 3 OASIS-HAE and OASISplus clinical trials. In the long-term OASISplus study, patients experienced a remarkable 94% average reduction in their monthly attack rate after one year of treatment.

"The EU approval of DAWNZERA is an important milestone that reflects our ongoing commitment to bring this innovative medicine to people in need across the globe,” said Brett P. Monia, Ph.D., chief executive officer at Ionis. “As the first and only RNA-targeted therapy for HAE, we believe DAWNZERA has the potential to become the prophylactic therapy of choice for many patients across the EU."

This high level of efficacy, combined with its convenient dosing, sets it apart. Current prophylactic options in Europe range from daily oral pills and twice-weekly injections to intravenous infusions administered every few days. For many patients, a self-administered injection once every one or two months represents a paradigm shift, transforming HAE from a condition that dictates daily life into a manageable part of it, freeing them from a relentless treatment schedule.

Reshaping a Competitive Market

DAWNZERA enters a dynamic and competitive European HAE market. It will vie for market share against established players like Takeda’s Takhzyro®, a subcutaneous injection given every two weeks, and BioCryst’s Orladeyo®, the only once-daily oral prophylactic. It also faces a new rival in CSL Behring's Andembry®, a once-monthly injection.

However, DAWNZERA's unique combination of a novel RNA-based mechanism, strong efficacy, and an extended dosing interval of up to eight weeks provides a powerful competitive advantage. This convenience factor is a key differentiator that could drive significant patient and physician preference.

The commercial rollout will be managed by Otsuka Pharmaceutical, which holds exclusive rights to the drug in Europe and the Asia-Pacific region. This strategic partnership allows Ionis to leverage Otsuka's established European commercial infrastructure and expertise in rare diseases. In return for the rights, Ionis received a $65 million upfront payment and is now eligible for a $15 million milestone payment following this EU approval. The agreement also includes tiered royalties of up to 30% on net sales, a structure that could generate substantial long-term revenue for Ionis, which projects global annual sales for DAWNZERA could surpass $500 million in the early 2030s.

“We are proud of the decision from the European Commission to authorize the use of DAWNZERA in HAE," said Andy Hodge, President and CEO at Otsuka Pharmaceutical Europe Ltd. "This represents another key milestone in the collaboration between Otsuka and Ionis which aims to address unmet need in a challenging rare disease.”

The Path to Patient Access and Affordability

While the European Commission's approval is a crucial first step, the journey to getting DAWNZERA into the hands of patients is far from over. Otsuka now faces the complex and country-specific process of negotiating pricing and reimbursement with national health technology assessment (HTA) bodies across the European Union.

Agencies like Germany’s Institute for Quality and Efficiency in Health Care (IQWiG) and France’s Haute Autorité de Santé (HAS) will meticulously scrutinize the drug’s clinical data, cost-effectiveness, and overall value compared to existing treatments. For a high-value rare disease drug, securing favorable reimbursement often requires demonstrating benefits beyond just attack reduction, including improvements in quality of life, reduced hospitalizations, and lower overall burden on the healthcare system.

The convenience of a self-administered therapy with an extended dosing interval will be a central part of this value argument. Fewer injections and doctor visits, coupled with greater patient autonomy, can translate into significant long-term savings and societal benefits. It is likely that Otsuka will engage in managed entry agreements or outcomes-based contracts in some markets, linking the drug's price to its real-world performance to manage budget impact for national payers. Patient advocacy organizations, which have long campaigned for better and more convenient treatments, will also play a critical role in advocating for broad and equitable access across the continent.

A Landmark for RNA-Targeted Medicine

The approval of DAWNZERA, which follows its authorization in the United States in August 2025, is more than just a new option for HAE; it's a significant validation of Ionis Pharmaceuticals' pioneering work in RNA-targeted therapies. These medicines are designed to intervene at the genetic level, preventing the body from producing the specific proteins that cause or drive a disease. This approach represents a frontier in precision medicine, offering the potential to treat a wide array of conditions that were previously difficult to manage.

As with any potent therapy, DAWNZERA carries potential risks. The drug's label includes a warning for hypersensitivity reactions, including the possibility of anaphylaxis, a severe allergic reaction. The most common side effects observed in clinical trials were injection site reactions, upper respiratory tract infections, and urinary tract infections.

The arrival of DAWNZERA in Europe underscores a powerful trend in modern medicine: the translation of cutting-edge science into tangible, life-altering treatments for patients with rare diseases. For the thousands of individuals with HAE, this approval represents not just a new medication, but the promise of a future with greater freedom, predictability, and control over their own lives.